ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis
Status:
Completed
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the incidences of GVHD and viral infections in
haploidentical hematopoietic stem cell transplant recipients receiving different dose of
antithymocyte globulin (ATG) for acute graft-versus-host disease(aGVHD) prophylaxis. Our
first objective was to investigate the optimal dose of ATG for aGVHD and second object was to
evaluate the effect of different dose of ATG on post-transplant viral infection.
Phase:
Phase 4
Details
Lead Sponsor:
Nanfang Hospital of Southern Medical University
Collaborators:
First Affiliated Hospital of Guangxi Medical University Fujian Medical University Union Hospital Guangxi Medical University Guangzhou General Hospital of Guangzhou Military Command Peking University People's Hospital Southern Medical University, China Xiangya Hospital